Education
About Us
Working with TipRanks
Follow Us
Atyr Pharma Inc. (DE:471A)
:471A
471A Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.32 - €4.84
Previous CloseN/A
Volume750.00
Average Volume (3M)409.00
Market Cap
€429.09M
Enterprise Value€487.70M
Total Cash (Recent Filing)€76.35M
Total Debt (Recent Filing)$12.99M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 13, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding89,004,430
10 Day Avg. Volume449
30 Day Avg. Volume409
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)6.28
Price to Sales (P/S)0.00
P/FCF Ratio-7.80
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue460.97
Enterprise Value/Gross Profit-1.27K
Enterprise Value/Ebitda-1.89
Forecast
1Y Price Target
€19.28Price Target Upside298.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
aTyr Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEfzo's interim update for its Ph2 in SSc-ILD is a nice positive showing early signs of activity and good safety.
Investor InterestInvestors are eagerly anticipating the Phase 3 trial results for efzofitimod in pulmonary sarcoidosis, indicating strong interest in the drug's potential.
Trial DesignEFZO-FIT has a solid chance of succeeding on its steroid reduction primary endpoint based on the favorable trial design and supportive Phase 1/2 data.
Bears Say
Data InterpretationThe addition of ATYR0101 to the development pipeline builds on the promising clinical results of the company's lead tRNA synthetase-derived therapy, efzofitimod, for the treatment of interstitial lung disease (ILD), currently in pivotal Phase 3 studies.
Data UncertaintyThe company did not provide specifics regarding the dose used in the patients, leading to some uncertainty in data interpretation.
Short-Term Data ConcernMinimal clinically important difference for SSc-ILD is an improvement of 4-6 points at 12 months, contrasting with the shorter-term data presented.
Options Prices
Currently, No data available
---
Ownership Overview
2.58% Insiders
30.12%
Mutual Funds
0.19% Other Institutional Investors
62.47% Public Companies and Individual Investors
471A FAQ
What was Atyr Pharma Inc.’s price range in the past 12 months?
Atyr Pharma Inc. lowest stock price was €1.32 and its highest was €4.84 in the past 12 months.
What is Atyr Pharma Inc.’s market cap?
Atyr Pharma Inc.’s market cap is €429.09M.
When is Atyr Pharma Inc.’s upcoming earnings report date?
Atyr Pharma Inc.’s upcoming earnings report date is Aug 13, 2025 which is in 61 days.
How were Atyr Pharma Inc.’s earnings last quarter?
Atyr Pharma Inc. released its earnings results on May 07, 2025. The company reported -€0.149 earnings per share for the quarter, beating the consensus estimate of -€0.168 by €0.018.
Is Atyr Pharma Inc. overvalued?
According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued.
Does Atyr Pharma Inc. pay dividends?
Atyr Pharma Inc. does not currently pay dividends.
What is Atyr Pharma Inc.’s EPS estimate?
Atyr Pharma Inc.’s EPS estimate is -0.16.
How many shares outstanding does Atyr Pharma Inc. have?
Atyr Pharma Inc. has 89,004,430 shares outstanding.
What happened to Atyr Pharma Inc.’s price movement after its last earnings report?
Atyr Pharma Inc. reported an EPS of -€0.149 in its last earnings report, beating expectations of -€0.168. Following the earnings report the stock price went down -2.143%.
Which hedge fund is a major shareholder of Atyr Pharma Inc.?
Currently, no hedge funds are holding shares in DE:471A
aTyr Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.28 (298.43% Upside)
€19.28 (298.43% Upside)
Blogger Sentiment
Bullish
DE:471A Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
184.97%
12-Months-Change
Fundamentals
Return on Equity
-79.51%
Trailing 12-Months
Asset Growth
-14.13%
Trailing 12-Months
Company Description
Atyr Pharma Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
471A Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Read More>471A Stock 12 Month Forecast
Average Price Target
€19.28
▲(298.43%Upside)
Technical Analysis
Arcturus Therapeutics
―
Olema Pharmaceuticals
―
ATAI Life Sciences
―
Monte Rosa Therapeutics
―
Aura Biosciences Inc
―